communityacquir
pneumonia
cap
lead
caus
death
due
infecti
diseas
worldwid
account
major
morbid
mortal
cost
streptococcu
pneumonia
domin
bacteri
caus
cap
despit
advanc
medic
care
mortal
pneumococc
pneumonia
still
rang
known
prognost
factor
mortal
due
pneumococc
pneumonia
includ
old
age
male
sex
preexist
lung
diseas
solid
organ
tumor
nosocomi
infect
leukopenia
low
bodi
temperatur
urea
nitrogen
level
mgdl
hypoalbuminemia
hypoxemia
septic
shock
high
sever
howev
preced
respiratori
viru
infect
rvi
potenti
risk
factor
sever
pneumococc
pneumonia
evalu
studi
due
unavail
routin
virolog
diagnost
observ
polymeras
chain
reaction
pcr
base
test
allow
detect
variou
respiratori
virus
coinfect
might
associ
sever
rapid
molecular
diagnost
techniqu
multiplex
nucleic
acid
pcr
assay
respiratori
viral
pathogen
recent
introduc
clinic
practic
recent
studi
one
respiratori
viru
infect
report
hospit
adult
patient
particularli
preced
rvi
long
regard
predispos
factor
pneumococc
viral
infect
caus
chang
respiratori
tract
includ
bronchoconstrict
increas
mucu
stronger
adhes
pneumococci
virusinfect
cell
uninfect
decreas
ciliari
damag
mucos
cell
dysfunct
howev
studi
regard
clinic
impact
preced
rvi
patient
pneumococc
pneumonia
limit
purpos
studi
evalu
clinic
signific
preced
rvi
clinic
sever
pneumococc
pneumonia
adult
retrospect
studi
perform
tertiari
care
hospit
seoul
republ
korea
januari
march
subject
includ
adult
patient
age
year
pneumococc
pneumonia
test
rvi
use
multiplex
revers
transcriptionpolymeras
chain
reaction
rtpcr
within
day
preced
pneumonia
isol
follow
death
hospit
discharg
case
defin
patient
sever
pneumonia
ie
determin
pneumonia
sever
index
psi
score
risk
class
control
defin
adult
patient
nonsever
pneumonia
ie
psi
score
risk
class
studi
protocol
approv
hospit
institut
review
board
also
waiv
requir
inform
consent
retrospect
studi
requir
deviat
routin
medic
practic
pneumococc
pneumonia
defin
acut
lower
respiratori
tract
infect
opac
infiltr
chest
radiograph
confirm
radiologist
plu
isol
pneumonia
sputum
sampl
outpati
inpati
within
hour
hospit
admiss
patient
receiv
antimicrobi
therapi
day
acut
lower
respiratori
tract
infect
defin
presenc
two
follow
symptom
sign
product
cough
fever
dyspnea
pleurit
chest
pain
crackl
septic
shock
defin
accord
standard
clinic
data
patient
diagnos
pneumococc
pneumonia
collect
computer
hospit
databas
singl
episod
per
patient
includ
studi
winter
season
patient
undergo
laboratori
test
rvi
within
day
preced
pneumococc
pneumonia
exclud
hospitalacquir
pneumonia
case
present
hour
admiss
within
day
hospit
discharg
also
exclud
patient
treat
antibiot
accord
local
practic
clinic
paramet
analysi
includ
demograph
clinic
characterist
comorbid
medic
pneumonia
treatment
antimicrobi
suscept
treatment
outcom
score
calcul
base
clinic
present
pneumonia
pneumoniarel
mortal
defin
accord
microbiolog
failur
persist
pneumoniaassoci
symptom
sign
absenc
definit
caus
death
blood
sputum
cultur
routin
perform
patient
present
emerg
room
admit
hospit
due
suspect
pneumonia
simultan
patient
preced
concurr
flulik
cold
symptom
underw
nasopharyng
swab
sampl
isol
respiratori
virus
clinic
isol
pneumonia
identifi
convent
biochem
method
vitek
gp
card
marci
letoil
franc
antimicrobi
suscept
determin
use
vitek
system
accord
revis
clinic
laboratori
standard
institut
interpret
criteria
nasopharyng
swab
sampl
test
respiratori
viru
pathogen
includ
influenza
viru
type
type
b
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
type
type
b
rhinoviru
parainfluenza
virus
piv
type
coronavirus
adenoviru
use
seeplex
rv
assay
seegen
inc
seoul
korea
base
multiplex
rtpcr
method
viral
dna
rna
extract
respiratori
specimen
use
kit
intron
biotechnolog
seoul
korea
accord
manufactur
instruct
nucleic
acid
amplif
conduct
use
seeplex
rv
master
mix
describ
demograph
clinic
characterist
compar
patient
sever
nonsever
pneumococc
pneumonia
independ
categor
variabl
describ
use
count
proport
compar
use
chisquar
test
fisher
exact
test
continu
variabl
express
mean
standard
deviat
median
interquartil
rang
iqr
twosampl
student
ttest
use
compar
continu
independ
variabl
normal
distribut
utest
use
compar
continu
independ
variabl
nonnorm
distribut
multivari
logist
regress
analys
use
backward
stepwis
variabl
select
base
logist
regress
statist
use
examin
impact
multipl
independ
predictor
clinic
sever
pneumococc
pneumonia
depend
variabl
goodnessoffit
test
perform
evalu
model
intern
accuraci
obtain
leaveoneout
crossvalid
use
evalu
perform
predict
model
statist
signific
defin
p
statist
analys
perform
use
ibm
spss
statist
version
ibm
corpor
armonk
ny
usa
r
r
foundat
statist
comput
vienna
austria
sa
sa
institut
inc
cari
nc
usa
studi
period
total
patient
visit
hospit
outpati
n
inpati
n
total
patient
multipl
episod
pneumonia
isol
sputum
cultur
initi
screen
patient
age
year
patient
undergo
multiplex
rtpcr
rvi
within
day
preced
pneumonia
isol
n
receiv
antibiot
therapi
day
n
acquir
pneumonia
hospit
n
exclud
studi
final
patient
pneumococc
pneumonia
analyz
studi
includ
outpati
hospit
patient
none
polymicrobi
infect
simultan
infect
site
median
iqr
psi
score
patient
pneumococc
pneumonia
respect
psi
class
observ
follow
class
ii
n
class
iii
n
class
iv
n
class
v
n
ninetynin
patient
sever
pneumococc
pneumonia
psi
score
one
hundr
thirtytwo
patient
receiv
rvi
test
throughout
influenza
season
northern
hemispher
novemb
april
fortyeight
patient
preced
concurr
rvi
detect
multiplex
rtpcr
perform
within
day
pneumonia
present
particular
influenza
b
rsv
infect
predomin
winter
month
studi
period
januari
march
shown
comparison
demograph
clinic
characterist
patient
sever
nonsever
pneumococc
pneumonia
shown
hypoalbuminemia
azotemia
thrombocytopenia
common
case
group
sever
pneumococc
pneumonia
control
group
nonsever
pneumococc
pneumonia
addit
anemia
hyperbilirubinemia
common
case
group
case
group
frequent
preced
rvi
control
group
case
group
multilobar
consolid
chest
radiograph
control
group
versu
respect
p
howev
signific
differ
complic
pleural
effus
case
control
group
versu
respect
p
treatment
clinic
outcom
sever
nonsever
group
compar
signific
differ
antimicrobi
therapi
intens
care
unit
hemodialysi
mechan
ventil
two
group
patient
two
group
receiv
appropri
antibiot
therapi
pneumococc
pneumonia
base
antimicrobi
suscept
result
twentythre
patient
receiv
antibiot
pneumococc
pneumonia
prior
arriv
hospit
significantli
differ
case
control
group
vs
respect
p
resist
rate
pneumococc
isol
penicillin
levofloxacin
significantli
higher
case
group
control
group
allcaus
inhospit
mortal
rate
pneumoniarel
mortal
rate
respect
median
length
hospit
stay
inpati
day
iqr
patient
sever
pneumococc
pneumonia
show
higher
pneumoniarel
mortal
longer
hospit
stay
patient
nonsever
pneumococc
pneumonia
multivari
logist
regress
analysi
preced
rvi
odd
ratio
confid
interv
ci
male
sex
ci
old
age
ci
hypoalbuminemia
ci
azotemia
ci
significantli
associ
sever
pneumococc
pneumonia
pvalu
goodnessoffit
test
p
henc
signific
evid
lack
fit
final
model
leaveoneout
crossvalid
perform
assess
predict
accuraci
final
model
auc
clinic
sever
model
raw
data
set
leaveoneout
crossvalid
leaveoneout
crossvalid
sensit
specif
posit
predict
valu
neg
predict
valu
obtain
optim
cutoff
point
studi
period
adult
patient
form
bacteri
pneumonia
underw
multiplex
rtpcr
test
rvi
within
day
preced
type
bacteri
isol
patient
coinfect
rvi
form
bacteri
pneumonia
staphylococcu
aureu
n
haemophilu
influenza
n
pseudomona
aeruginosa
n
klebsiella
pneumonia
n
preced
rvi
detect
patient
includ
influenza
viru
n
hmpv
n
rhinoviru
n
rsv
n
mix
viral
infect
n
rsv
plu
coronaviru
coronaviru
plu
piv
rhinoviru
plu
piv
patient
preced
rvi
form
bacteri
pneumonia
compar
postvir
pneumococc
pneumonia
median
iqr
versu
respect
p
psi
score
versu
respect
p
sever
pneumococc
pneumonia
versu
respect
p
allcaus
inhospit
mortal
rate
versu
respect
p
pneumoniarel
mortal
rate
versu
respect
p
significantli
differ
howev
adult
patient
form
bacteri
pneumonia
preced
rvi
significantli
associ
sever
pneumonia
patient
sever
pneumonia
versu
patient
nonsever
pneumonia
p
studi
investig
impact
preced
rvi
clinic
sever
pneumococc
pneumonia
preced
rvi
male
sex
old
age
hypoalbuminemia
azotemia
identifi
risk
factor
significantli
associ
sever
pneumococc
pneumonia
psi
score
valid
multivari
model
design
predict
clinic
sever
studi
least
one
respiratori
viru
detect
patient
within
day
preced
pneumonia
present
common
viral
pathogen
detect
decreas
frequenc
influenza
viru
rsv
piv
accord
three
prospect
studi
coinfect
present
adult
studi
jen
et
rhinoviru
common
viru
identifi
mix
viral
bacteri
infect
adult
cap
follow
rsv
influenza
viru
find
indic
quarter
patient
present
pneumococc
pneumonia
rvi
preced
day
studi
preced
rvi
one
independ
risk
factor
associ
sever
pneumococc
pneumonia
higher
psi
score
suggest
potenti
role
preced
rvi
clinic
sever
previou
studi
also
report
coinfect
adult
cap
associ
higher
psi
risk
bacteri
hypoalbuminemia
azotemia
host
factor
ie
male
sex
increas
age
also
associ
clinic
sever
pneumococc
pneumonia
known
prognost
factor
mortal
patient
outpati
hospit
patient
studi
inhospit
mortal
rate
pneumococc
pneumonia
compar
hospit
patient
mortal
among
outpati
includ
patient
sever
pneumonia
inhospit
mortal
rate
versu
respect
p
pneumococc
pneumoniarel
mortal
rate
versu
respect
p
significantli
differ
patient
preced
rvi
without
preced
rvi
studi
frequent
preced
rvi
influenza
influenza
season
novemb
april
influenza
viru
infect
demonstr
import
predispos
factor
subsequ
pneumococc
pneumonia
hypothes
synergist
interact
two
pathogen
includ
epitheli
damag
chang
airway
function
upregul
receptor
chang
innat
immun
season
distribut
preced
rsv
hmpv
infect
overlap
winter
spring
period
piv
infect
distribut
june
august
interact
pneumococcu
respiratori
virus
also
suggest
rsvinduc
impair
macrophag
neutrophil
function
cytokin
signal
increas
risk
pneumococc
infect
murin
hmpv
piv
pneumococcu
coinfect
also
demonstr
act
synergist
mous
studi
period
patient
form
bacteri
pneumonia
coinfect
rvi
aureu
n
h
influenza
n
p
aeruginosa
n
k
pneumonia
n
contrast
pneumococc
pneumonia
preced
rvi
significantli
associ
sever
pneumonia
patient
form
bacteri
pneumonia
accord
studi
screen
earli
detect
rvi
patient
sever
pneumococc
pneumonia
might
warrant
appropri
antivir
therapi
prevent
intrahospit
transmiss
prevent
strategi
includ
vaccin
season
influenza
pneumococc
diseas
alreadi
emphas
influenza
season
studi
certain
limit
first
singlecent
studi
limit
number
case
subject
underw
laboratori
test
rvi
might
associ
select
bia
multiplex
rtpcr
test
respiratori
virus
introduc
clinic
practic
recent
therefor
mani
clinician
still
low
level
test
awar
patient
preced
concurr
flulik
cold
symptom
chosen
rvi
test
secondli
number
patient
rvi
influenza
limit
abil
determin
differ
viral
pathogen
affect
clinic
sever
pneumococc
pneumonia
thirdli
retrospect
observ
studi
includ
patient
pneumococc
pneumonia
receiv
antibiot
therapi
day
base
clinic
diagnosi
outcom
therefor
studi
may
repres
untreat
patient
pneumococc
pneumonia
howev
patient
die
within
day
admiss
among
patient
pneumonia
isol
sputum
cultur
receiv
antibiot
therapi
day
fourthli
incid
pneumococc
bacteremia
low
studi
might
partli
due
exposur
antibiot
obtain
first
blood
cultur
patient
studi
design
includ
patient
pneumococc
pneumonia
virolog
test
rvi
prior
isol
pneumococci
sputum
cultur
conclus
preced
concurr
rvi
might
significantli
influenc
clinic
sever
patient
pneumococc
pneumonia
addit
factor
male
sex
old
age
hypoalbuminemia
azotemia
studi
need
understand
role
preced
concurr
rvi
determin
clinic
benefit
routin
viral
diagnost
test
rvi
patient
pneumococc
pneumonia
